IMGN - ImmunoGen, Inc.
| Previous Close | 3.3500 |
| Open | 3.3200 |
| Bid | 1.7900 x 4000 |
| Ask | 0.0000 x 3100 |
| Day's Range | 3.1400 - 3.3486 |
| 52 Week Range | 1.7600 - 6.1300 |
| Volume | 918,626 |
| Avg. Volume | 1,596,366 |
| Market Cap | 521.719M |
| Beta (3Y Monthly) | 2.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0190 |
| Earnings Date | Feb 6, 2020 - Feb 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.67 |
- Thomson Reuters StreetEvents
Edited Transcript of IMGN earnings conference call or presentation 1-Nov-19 12:00pm GMT
Q3 2019 ImmunoGen Inc Earnings Call
- Insider Monkey
Is ImmunoGen, Inc. (IMGN) A Good Stock To Buy?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- Business Wire
ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting
Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN
- Simply Wall St.
How Many ImmunoGen, Inc. (NASDAQ:IMGN) Shares Do Institutions Own?
A look at the shareholders of ImmunoGen, Inc. (NASDAQ:IMGN) can tell us which group is most powerful. Insiders often...
- Zacks
ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally
ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.
- Zacks
ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates
ImmunoGen (IMGN) delivered earnings and revenue surprises of 21.05% and 45.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
Full Mirvetuximab Soravtansine Phase 3 FORWARD I and Initial Phase 1b FORWARD II Triplet Data Presented at ESMO
- Zacks
ImmunoGen (IMGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 1, 2019 to discuss its third quarter operating results. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days.
- Simply Wall St.
Did ImmunoGen, Inc. (NASDAQ:IMGN) Insiders Buy Up More Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- Business Wire
ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety and overall response data from the Phase 1b FORWARD II triplet cohort evaluating mirvetuximab in combination with carboplatin and Avastin® (bevacizumab) in patients with recurrent, platinum-sensitive ovarian cancer at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
- Business Wire
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
ImmunoGen, Inc. (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced full data and additional exploratory analyses from the Phase 3 FORWARD I study evaluating mirvetuximab soravtansine compared to chemotherapy in women with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer during an oral presentation at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
- Thomson Reuters StreetEvents
Edited Transcript of IMGN earnings conference call or presentation 2-Aug-19 12:00pm GMT
Q2 2019 ImmunoGen Inc Earnings Call
- Zacks
ImmunoGen (IMGN) Up 18.8% Since Last Earnings Report: Can It Continue?
ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.
Motley FoolImmunogen Inc (IMGN) Q2 2019 Earnings Call Transcript
IMGN earnings call for the period ending June 30, 2019.
- Zacks
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.
- Motley Fool
What You'll Want to Know About ImmunoGen's Q2 Results
The clinical-stage biotech appears to be in solid financial shape as it moves toward a pivotal clinical study for its lead pipeline candidate.
- Zacks
ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates
ImmunoGen (IMGN) delivered earnings and revenue surprises of 9.38% and 50.46%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- ACCESSWIRE
ImmunoGen, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2019 / ImmunoGen, Inc. (NASDAQ: IMGN ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 2, 2019, 2018 at 8:00 AM ...
- Zacks
Earnings Preview: ImmunoGen (IMGN) Q2 Earnings Expected to Decline
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
